Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
Status:
Active, not recruiting
Trial end date:
2022-08-19
Target enrollment:
Participant gender:
Summary
This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different
lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373).The study will enroll
approximately 900 previously vaccinated adults 18 to 49 years of age, inclusive.